Moore Capital Management
ESPR icon

Moore Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Moore Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-45,000
Closed -$2.25M – 265
2017
Q3 		$2.25M Buy
+45,000
New +$2.17M 0.04% 156

Other funds holding ESPR

BB Biotech
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Pentwater Capital Management
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Credit Suisse
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Moore Capital Management's ESPR Position: Q4 2017 in Review

Moore Capital Management sold out of Esperion Therapeutics (ESPR) in Q4 2017, closing a stake of 45,000 shares — an estimated $2.25M sold.

Moore Capital Management first reported a position in ESPR in Q3 2017 and held it in 1 quarter. The position peaked at $2.25M in Q3 2017. 165 funds tracked by Wall St. Rank hold ESPR as of Q4 2017.

  • Moore Capital Management reported no remaining Esperion Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Moore Capital Management sold 45,000 Esperion Therapeutics shares in Q4 2017, an estimated $2.25M.
  • Moore Capital Management first reported a position in Esperion Therapeutics in Q3 2017 and held it in 1 quarter.
  • Moore Capital Management's Esperion Therapeutics position peaked at $2.25M in Q3 2017.
  • 165 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2017.

Based on Moore Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.